A large observational study published October 15 in JAMA Network Open found that GLP-1 receptor agonists (GLP-1RAs)—drugs often prescribed for weight loss such as semaglutide and tirzepatide products—were associated with the largest reduction in major cardiovascular events among adults with type 2 diabetes compared with three other glucose‑lowering drug classes.
Study design and sample
– Researchers analyzed electronic health records from more than 240,000 adults with type 2 diabetes who started one of four medication classes between 2014 and 2021 across six U.S. healthcare systems. The average age was 57 and 54% were male. Metformin was not part of this analysis.
– Medication classes compared: sulfonylureas (older insulin secretagogues), DPP‑4 inhibitors (oral incretin enhancers), SGLT2 inhibitors (renal glucose excretion agents), and GLP‑1 receptor agonists (injectable agents that improve glucose control and promote weight loss).
– Outcomes evaluated were nonfatal myocardial infarction, nonfatal stroke, and cardiovascular death (analyzed individually and as a combined outcome).
Key findings
– Cardiovascular risk differed by drug class. Sustained use of GLP‑1RAs was linked to the greatest reduction in the composite outcome (nonfatal MI, nonfatal stroke, and CV death), followed by SGLT2 inhibitors, sulfonylureas, and DPP‑4 inhibitors.
– The results align with prior randomized trials and observational studies showing cardiometabolic and renal benefits for GLP‑1RAs and SGLT2 inhibitors, though specific effect sizes and populations varied.
– As an observational study of routine care, the findings show association rather than definitive causation; treatment choice should be individualized.
Why GLP‑1RAs may lower cardiovascular risk
– GLP‑1RAs mimic an endogenous hormone that regulates appetite and glucose, producing weight loss, improved glycemic control, and favorable effects on blood pressure and lipid profiles.
– They may also have direct vascular and cardiac protective actions. Newer agents such as tirzepatide combine GLP‑1 and GIP activity and tend to produce larger weight loss and metabolic improvements.
Expert perspectives
– Clinicians quoted in the study commentary characterized the work as addressing an important clinical question and consistent with growing evidence that GLP‑1RAs offer cardiometabolic benefits. Some noted the largest apparent benefits were seen in older patients with more comorbidities.
Safety, limitations, and clinical context
– Common adverse effects of GLP‑1RAs include gastrointestinal symptoms (nausea, diarrhea, constipation) and risk of excess weight loss or loss of muscle mass in some patients. Less common but serious risks include pancreatitis and gallbladder disease; agents are contraindicated for people with certain hereditary thyroid cancers.
– Limitations: the analysis is observational, metformin was not evaluated, and residual confounding is possible. Cost and tolerability are practical barriers for some patients.
– Broader context: roughly 38 million people in the U.S. have diabetes, most with type 2. Diabetes increases risks of cardiovascular disease, kidney disease, eye disease, neuropathy, and stroke. Medications are most effective when combined with lifestyle measures—healthy diet, regular physical activity, tobacco avoidance, moderated alcohol use, adequate sleep, and stress management.
Bottom line
GLP‑1 receptor agonists were associated with the greatest reduction in major cardiovascular events among the four glucose‑lowering drug classes studied in adults with type 2 diabetes. Clinicians should balance these potential benefits against side effects, costs, and individual patient factors, and continue to emphasize comprehensive lifestyle care alongside pharmacotherapy.
